CD274 and neoplasm: Determining the characteristics of WL12 peptide binding to PD-L1 also presents opportunities to quantify the pharmacologic activity of PD-L1 antibodies within the tumor bed in a manner agnostic to the antibody type, as recently shown in preclinical models (20).